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Long-term oxygen therapy (LTOT) is the cornerstone mode of treatment in patients with severe chronic obstructive pulmonary
disease (COPD) associated with resting hypoxaemia. When appropriately prescribed and correctly used, LTOT has clearly been
shown to improve survival in hypoxemic COPD patients. Adherence to LTOT ranges from 45% to 70% and utilization for more
than 15 hours per day is widely accepted as eﬃcacious. Although several studies have addressed the level of patients’ adherence
to LTOT, few have suggested or evaluated interventions that conduce to compliance enhancement. The lack of suﬃcient data
regarding COPD patients following oxygen prescription is an enormous void that must be duly confronted to augment clinical
eﬀectiveness and cost containment for the long term use. The present review article highlights factors inﬂuencing the compliance
of patients using LTOT and emphasizes novel strategies and interventions that may prove to be of signiﬁcant beneﬁt given the
remarkably little current research appraising this issue. Therefore, additional research should be promptly performed to verify the
eﬃcacy of newly designed approaches in improving the outcomes of patients receiving LTOT.
1.Introduction
It is well established that long-term oxygen therapy (LTOT)
is the only therapeutic modality proven to alter the late
course of chronic obstructive pulmonary disease (COPD).
Particularly, two landmark studies, the Nocturnal Oxygen
Therapy Trial (NOTT) and the British Medical Research
Council (MRC) conducted in the late 1970s have explic-
itly demonstrated that LTOT (when used for more than
15hours/day) improves survival rates in patients with severe
COPD associated with resting hypoxemia [1, 2]. In terms
of maximum beneﬁt, continuous oxygen administration
(≥15h/d) is superior to intermittent or nocturnal use
[3]. There is also accumulating evidence that LTOT has
favourable eﬀects on other outcome measures, including
depression, cognitive function, quality of life, exercise
capability, and frequency of hospitalization [4–10]. More-
over, it stabilizes and sometimes reverses the progression
of pulmonary arterial hypertension and it diminishes as
well cardiac arrhythmias and electrocardiographic ﬁndings
indicative of myocardial ischemia [11, 12].
The eﬀectiveness of LTOT in improving survival has
been substantiated only in stable COPD patients with severe
chronic hypoxemia (PaO2 less than 55mmHg (7.3kPa)
or PaO2 ranging from 56 to 59mmHg (7.4–7.8kPa) in
presence of signs of cor pulmonale, hematocrit > 55%) [13].
The resultant clinical beneﬁts of LTOT are contingent on
the treatment compliance, the treatment duration, and the
adequate correction of hypoxemia.
Despite the generally recommended daily duration of
oxygen use (>15h/day) to achieve its goals, the adherence to
LTOT seems to be poor according to the existing literature
[14]. Furthermore, this therapy incurs great expenses to the
healthcare systems worldwide because of several hundred
of thousands of COPD patients receiving supplemental
oxygen and the high expenditures pertinent to durable
delivery oxygen equipment. In particular, it is estimated
that 1 million patients receive LTOT in the USA with total
Medicare reimbursements for costs related to O2 exceeding $
2billion/year[15, 16]. It is likely that a great deal of money is
dissipated since several studies report inadequate adherence
rates to this treatment [17].2 Pulmonary Medicine
The aim of this paper is to review nonadherence to LTOT
for COPD within the context of chronic care management,
factors aﬀecting suboptimal compliance and methods evalu-
ating it as well as strategies that may enhance it.
2. LTOT Prescription
The actual current guidelines are in strong agreement
in recommending LTOT for severely hypoxaemic COPD
patients (PaO2 < 55mmHg, < 7.3kPa), whereas some
diﬀerences have been observed in patients with moderate
hypoxaemia (55 < PaO2 < 60mmHg, 7.4 < PaO2 > 8kP a)
regarding the criteria which should be associated with PaO2
values [18].
Much of the initial research for LTOT addressed the
precision of the prescription. In particular, the prescription
ofoxygenadministrationforatleast15h/dayisconsideredto
be adequate and it represents one variable that is associated
with eﬀective usage [19]. Howard et al. reported that physi-
cians “varied widely in their prescribing habits”. 36% out of
LTOT patients were prescribed less than 15 hours per day
thus reducing optimal dosage [20]. Walshaw and coworkers
concluded that an eﬀective prescription and compliance was
associated with a respiratory physician more often than a
family doctor [21]. Granados et al. mentioned that 58% of
the selected sample met the criteria for oxygen therapy, of
these 80.5% (29/36) were correctly prescribed with corrected
hypoxemia [22]. Another study found that 55% of patients
had not received thorough written instructions regarding the
use of LTOT by their physician and 63% were not aware of
LTOT importance in the therapeutic management of their
disease [23]. The lack of explicit prescription instructions
and prescription review does limit patient adherence.
3. LTOT Adherence
The minimum recommended duration of LTOT is 15h/day
thus representing an adequate oxygen adherence, as it has
been established and deﬁned by international guidelines on
domiciliary LTOT. Several studies have evaluated compliance
to LTOT showing rates ranging from 45 to 70% [20–32].
These clinical trials have determined the extent of patients’
oxygen use as well as identiﬁed problems. Annotations
from these studies indicate potential research direction
such as patient and oxygen provider education and/or
postprescription support. Table 1 summarizes these studies
with their associated discussion and suggested research. The
inadequate adherence to LTOT further suggests that patients
may not strongly perceive the clinical beneﬁts that have been
described by its continuous use. Furthermore, suboptimal
adherence has been reported as an independent modiﬁable
risk factor of frequent COPD exacerbations necessitating
hospital admissions thus increasing health care costs [33].
4. Risk Factors for LTOT Noncompliance
A multitude of factors has been proposed and identiﬁed
having negative impact on patients’ compliance with LTOT.
In particular, Cullen attempted to classify all the possible
implicated factors in poor adherence to oxygen therapy, as
shown in Table 2 [14].
Several studies have thoroughly reported the related
r e a s o n st oap a t i e n t ’ sr e l u c t a n c et ow e a rac a n n u l ao r
receive oxygen source device for at least 15h/day. In the
ﬁrst conducted study in early 1980s, only two of 14 patients
receiving oxygen through concentrator were complied with
the prescribed dose of 15h/day. The nonadherence was
attributed to prescribed ﬂow rate, machine problems, and
hypercapnia [25].
Oxygen therapy has induced restriction as well as it has
turned out to be threatening to mastery over symptoms
because of concerns about dependency and addiction [34].
Patients receiving oxygen from a stationary source are
tethered to it, and this in itself may limit their activities
of daily living. Many ambulatory sources are bulky and
heavy, discouraging, if not preventing, ambulation by elderly
patients and others with impaired strength and endurance
[35].
Patients may also experience side eﬀects due to oxygen
usesuchasnasaldryness,nasalbleeding,dizziness,someloss
of taste and smell, and unpleasant cosmetic eﬀects. These
are more noticeable when the oxygen is delivered through
dual prong nasal cannulae. Kampelmacher et al. in their
circumstantial study investigated the complaints of patients
prescribed LTOT. Of 528 participants, 108 were smokers and
15 of these smoked while using oxygen. 20% of patients used
oxygen less than prescribed due to treatment diﬃculties, lack
of breathlessness, or fear of oxygen addiction. Nonadhering
patients were primarily males and were ashamed of their
therapy and the associated stigma. Patient complaints were
related to restricted autonomy (50%), the delivery device
(41%), oxygen source (38%), feeling ashamed (38%), and
treatment duration (8%) [36].
Many patients may limit ambulatory O2 administra-
tion because of embarrassment, not wanting to be seen
publicly with the recognizable stigma of smoking-related
lung disease. Oliver studied COPD patients’ views of their
impaired lungs viasemistructured qualitative interviews and
concluded that nonadherence to treatment can be imputed
to perception of the patient’s doctor. If limited, failure to
seekmedicalcounselingwasnoted[37].Moreover,inastudy
carried out by Earnest describing and explaining the patterns
ofadherencetosupplementaloxygenin patients withhypox-
emic COPD, it was found that the majority of individuals
had a single conversation with their doctors about oxygen
that occurred at the time of their initial prescription [35].
The absence of clinician-patient communication at regular
intervals may compromise LTOT compliance.
The lack of substantial beneﬁts of treatment from
the patients’ standpoint might be another reason for the
decreased duration of oxygen utilization soon after its
initiation. Physicians looking after patients under LTOT
quite often hear the following statement: “I breathe oxygen,
butIdonotseeanyimprovement.”Patientsmostlyanticipate
an immediate positive eﬀect of oxygen therapy conﬁrmed by
the improved exercise tolerance. Since the patients do not
exhibit that, they feel frustrated and less enthusiastic about
continuing the treatment [32].Pulmonary Medicine 3
Table 1: Overview of adherence evaluation for LTOT.
Source Subjects/methods Adherence outcome percent or M (SD) Comments
future research needs
Evans et al. [25]
14 Concentrator patients
Evaluated usage in comparison
to prescribed 15hours/day
M = 13.3 (2)h/d Patient home respiratory support
needed
Vergeret et al. [27]
159 Hypoxic COPD patients
Two randomly assigned groups
to ﬁxed unit only or ﬁxed plus
portable unit
Fixed: M = 14 (3) h/d
Portable: M = 17 (3.5)h/d
Oxygen use and quality of life
increased with portable use.
Equipment aesthetics and
supervision during the ﬁrst three
months needed
Walshaw et al. [21] 61 patients reassessed for use and
prescription appropriateness
45.9% inadequate prescription 29.5%
compliance with correct prescription
Clinician and patient education
should be enhanced
Howard et al. [20]
531 concentrators after use
Compared prescription and
concentrator clocks
Prescription <15h/d then
Actual use M = 9.9h/d
Prescription >15h/d then
Actual use M = 13.4h/d
LTOT is complex and education
for rationale disease
management needed. Regular
home care is necessary
Restrick et al. [29] 176 patients interviewed and
followed up 74% used 12 + h/d
Reassessment necessary. Greater
communication among
providers
Morrison and Stovall
[10]
630 LTOT patients 79% were
COPD
Database evaluation for three
years
M = 14.9h/d
4 4 %w a sl e s st h a n1 5h / d
Instruction needed at time of
prescription but also followup
later when clinically stable
P´ epin et al. [19]
930 COPD patients
Compared prescription and
actual use
45% achieved 15 + h/d
Prescription M = 16h/d
Actual use M = 14.5h/d
Education at prescription needed
and more prospective
educational intervention studies
necessary
Granados et al. [22]
62 LTOT patients participated
70% were COPD
Evaluated compliance and if
hypoxemia was corrected
31% met all criteria for adherence to
adequate prescription
61% measured as compliant
Therapeutic process is noted as
prescription, oxygen device, and
compliance. Chronic care
requires reassessment
Ringbæk et al. [28]
125 of 182 LTOT patients
surveyed and evaluated as to
activities and portable oxygen
use
65% acceptable compliance
Ambulatory use positively aﬀected
compliance
Need to discuss how and when
LTOT is used and portable
oxygen options needed
Atis ¸e ta l .[ 30] 379 of 1100 patients responded
to questionnaire
28.2% self-reported use was 15 + h/d
M = 9h/d
Physician instruction and
followup produced greater use by
patients
Katsenos et al. [23] 249 LTOT patients
75% were COPD patients
26.9% complied.
55% did not receive precise written
instructions concerning LTOT. 63%
did not know LTOT importance for
the management of COPD
A well-organized home care
program may check LTOT utility
and enhance its eﬃcacy in COPD
patients
Lacasse et al. [31]
24 hypoxic COPD patients were
allocated to three interventions:
oxygen concentrator only,
concentrator plus as-needed
ambulatory oxygen and
concentrator plus ambulatory
compressed air.
Comparison of home-based
oxygen therapy alone with
ambulatory oxygen added to
home-based oxygen
Concentrator use: 18h/day
Concentrator plus ambulatory oxygen:
17.4h/day
Concentrator plus ambulatory
compressed air: 18h/day
The widespread provision of
portable oxygen-dependent
COPD patients is not justiﬁed.
The eﬃcient use of ambulatory
oxygen in a successful course of
respiratory rehabilitation
remains to be determined
Nasiłowski et al. [32]
30 patients under LTOT (77%
COPD patients) were followed
up for14 consecutive months
37% compliance.
Higher compliance (48%) during the
ﬁrst month. Nurses’ frequent home
visits did not increase compliance.
Noise produced by concentrator
inﬂuenced signiﬁcantly the compliance
An alternative oxygen source,
which would not generate any
noise or electricity consumption
m a yp o s i t i v e l ya ﬀect the
compliance4 Pulmonary Medicine
Table 2: Factors inﬂuential to patient adherence.
Illness factors Personal/family factors
Illness characteristics Demographic factors
Treatment complexity Patient/Family functioning
Attitudes toward LTOT Cognitive factors (e.g., health literacy)
Disease severity can adversely aﬀect LTOT adherence.
COPD in its late stages is a debilitating disease leading
to notably poor quality of life. Jones reported that poor
functional status for patients is related to depression and
feelings of minor support which may translate to inadequate
compliance [38]. Symptom management, mainly dyspnea
might aﬀect adherence, according to Earnest’s study ﬁndings
[35]. Several participants could tell little diﬀerence in how
they felt whether they were using oxygen or not. This group
of patients, who felt little but immediate beneﬁt in symptom
alleviation, struggled more with the role of oxygen in their
lives.
Additionally, poor adherence to LTOT prescriptions may
result from associated mental confusion or misunderstand-
ing of the correct prescription. COPD patients with low
educational level may be noncompliant with LTOT. Illiteracy
toincomprehensiblewrittenmedicalinstructionscontaining
scientiﬁc terms may lead to inadequate oxygen usage.
Accordingly, prescribing physicians should simplify their
instructionsonLTOTinilliteratepatients.Moreover,oldage,
portableoxygensystemstomobilepatients,highPaO2 values
on room air, and smoking habits comprise potential factors
withnegativeinﬂuenceonLTOTcompliance[39,40].COPD
hypoxaemic patients, who are active smokers, prefer keeping
on smoking to using advisable oxygen therapy resulting in
detrimental health consequences.
To recap, Marinker mentioned three rationales that typi-
cally explain general nonadherence behavior to medications,
given that LTOT is a controller medication [41]. First,
patients fear developing immunity if the medication is used
for a long period. Second, manufactured materials are not
natural; therefore they are not used and thirdly, addiction
or dependence may result, or tolerance will develop to the
beneﬁcial eﬀects of the medication.
5. Methods for Enhancing Adherence to LTOT
Despitetheeﬀecti v enessofL T O T ,asithasbeenc onﬁrmedb y
the apparent relationship between daily duration of oxygen
use (>15h/d) and survival, adherence remains poor. There-
fore, it is incumbent on the clinicians to make strenuous
eﬀorts to improve adherence to therapy among their patients
who receive oxygen. In this section, a comprehensive report
will be performed on the existing literature with regard to
strategies that may ameliorate LTOT compliance.
Current methods used to determine LTOT adherence
probably overestimate actual use. Each mode of oxygen
source utilized for LTOT requires a diﬀerent way of objective
adherence assessment. The daily use of the concentrator is
calculated using a time counter attached to the device syn-
chronized with its functional status. For oxygen compressed
cylinders, adherence is estimated by knowing the prescribed
ﬂow rate and the number of cylinders used. For liquid
oxygen, adherence is measured by weighing the container,
knowing the ﬂow rate, and estimating the amount of evapo-
ration and venting from the system. But the aforementioned
calculations are deﬁcient and probably misleading, since (a)
they cannot distinguish whether or not the patient is really
inhaling oxygen, as opposed to merely having the device
switched on (e.g., oxygen consumption may not reﬂect
oxygen delivery to the patient), and (b) they do not provide
precise information concerning the timing of daily oxygen
use. Lin et al. recently developed a novel oxygen adherence
monitor that objectively measures patients’ oxygen use [42].
The monitor attaches to the oxygen delivery system and
detects pressure in the tubing, including the respiratory-
related pressure ﬂuctuations transmitted from the nares. It
was designed to detect when the oxygen source is turned on
and when the patient is indeed wearing the nasal cannula
and receiving treatment. Lin et al. demonstrated that the
monitor was most precise in detecting patients not wearing
cannula thus yielding 100% speciﬁcity. The most challenging
recording situation was noted during sleep, and results
showed that accuracy may be decreased in patients with
mouth breathing pattern and frequent apneas/hypopneas.
However, the monitor’s ability to objectively evaluate oxygen
delivery, rather than oxygen expended, may contribute to the
improvement of patients’ adherence to LTOT.
Regular followup and sincere clinician-patient commu-
nication inﬂuence positively on LTOT adherence [20]. A
well-organized home care program for COPD patients is
the cornerstone of a positive attitude of patients regarding
LTOT thus improving its eﬃcacy [23, 43]. It is often not
appreciated that oxygen is a drug and should therefore be
prescribed with due care. Inappropriate LTOT prescriptions
can signiﬁcantly limit patients’ independence and in some
cases can cause signiﬁcant morbidity as well as might lead
to unjustiﬁably escalating oxygen costs [44]. Hence, written
prescription and precise instructions given by the treating
physician regarding LTOT use are indispensable factors
aﬀecting adherence. More education is essentially needed
in LTOT assessment and management. Due to signiﬁcance
of frequent followup, oximetry is necessary to conﬁrm the
necessity and the implementation of prescription. Zhu et al.
reported that continuous oximetry reduced liter ﬂow and
enhanced use at the desired level [45].
Furthermore, the true relationship and communication
between physician and patient is instrumental in LTOT
compliance. Clinicians involved in LTOT need to be aware
and work with the patients to facilitate their use of oxygen.
They should conduct a return demonstration and ask the
patient to repeat instructions. Oxygen devices are complex
andrequiremultipletasks.Returndemonstrationofthetasks
reﬂects patient capability. Physicians must discuss with their
patients LTOT use on an ongoing basis. More speciﬁcally,
erroneous beliefs about oxygen use, such as fear of addiction
and dependence, stigma, isolation, and embarrassment can
be tackled easily through patient-doctor conversation [14,
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Formal training about appropriate oxygen use has been
suggested as an important strategy for adherence improve-
ment. In one study, questionnaires regarding patients’
understanding about oxygen usage, their disease process,
oxygensafety,andsmokingstatuswereadministeredaftersix
months of education [47]. In the intervention group, 82%
were using their concentrator greater than 15 hours per day
as compared to 44% of the control group. Accordingly, 93%
of intervention patients understood the purpose and hazards
of oxygen, while this was true for only 41% of the control
group. Interestingly, smoking occurred with one patient in
the intervention group and six patients in the control group.
Family training and social support have also been
identiﬁed as considerable factors aﬀecting positively com-
pliance. In their study, Ring and Danielson reported that
social reinforcement is necessary to ensure understanding
for the complexity of the oxygen regimen [48]. Cornford
suggested strategies which have been adopted by patients on
domiciliary oxygen to maintain control and mastery over
their daily lives [34]. For seven of 24 patients using oxygen
over 15h/day, it was used to maintain feelings of indepen-
dence through relief of breathlessness during daily activities,
individual experimentation with the best ways to use it, and
reassurance that it was available to be used if necessary.
As to oxygen delivery systems, equipment convenience
has been demonstrated as another key factor to adherence
improvement [36]. Individuals extremely limited by the
weight and bulk of compressed gas in a tank could be
switched to concentrators or liquid systems at less than
half the weight. Recent studies showed that patients under
concentrators complained of machinery noise and increased
costs of electricity whereas the absence of noise and the
lack of dependence on electricity observed in stationary
liquid oxygen users might exert a beneﬁcial eﬀect on patient
compliance to LTOT [32, 49]. Other studies found increased
duration of oxygen therapy when LTOT recipients were
employing portable oxygen sources [28].
A stationary oxygen concentrator or liquid oxygen with
incorporated tubing up to 50 feet in length, in conjunction
with an additional small M-6 cylinder (2kg, 4h use) or
a small portable liquid reservoir (∼2kg, 5h use) is an
ideal and complete home oxygen system. Portable oxygen
concentrators might be an alternative to compressed or
liquid oxygen portable systems. They can be powered by
house current, an automobile’s electrical system, or by a
self-contained battery. Their two main disadvantages are
the weight (∼5kgs) and their short duration (1–3 hours)
on their own batteries. To be out and about for ﬁve or
more hours would require additional fully charged batteries
to replace those as they become fully discharged. This
equipment combination provides uninterrupted LTOT since
it facilitates patient movements within the home or out into
the community [50].
However, a major drawback of both of the traditional
continuous ﬂow LTOT portable systems is the limited
amount of time the patients could be away from their
stationary system. The introduction of oxygen-conserving
technology oﬀered an innovative solution [51]. Rather
than delivering oxygen continuously, an oxygen-conserving
device (OCD) dispenses oxygen only intermittently, and par-
ticularlyapresetvolumeorbolusofoxygeninresponsetothe
patient’s inspiratory eﬀort (or demand), as detected through
the nasal cannula. OCDs allow patients to spend consid-
erably more time away from the stationary system than
continuous ﬂow. Nevertheless, the actual length of time a
particular cylinder or liquid oxygen canister will last for with
an OCD depends on cylinder/canister size and capacity, the
model of OCD being used, and the patient’s respiratory rate.
Although traditional portable LTOT systems employing
OCD technology have been used successfully for the past
3 decades, one important matter remains: the amount of
time a patient may be away from his stationary system is
limited. Since one of the biggest fears LTOT patients have is
“oxygen depletion,” ambulation is somewhat restricted with
traditional LTOT systems. Patients are mindful of returning
home to their stationary system before their portable source
is totally used up. There are also issues associated with the
ongoing need to contact the home-care provider to schedule
home deliveries to provide the required reﬁlls, and the
anxiety of not knowing if the delivery will take place in time
for their next outing. On the other hand, oxygen suppliers
are equally dealing with their own uncertainties. Since one
of the major uncompensated costs that providers encounter
is repetitive home deliveries to replenish depleted contents,
thereis growingconcernthatthefrequencyofsuchdeliveries
might be further curtailed. Moreover, there is accumulating
evidence that patients with COPD who perform a relatively
high level of physical activity in their daily life on a sustained
basis have a considerably reduced risk of readmission due
to an exacerbation [52]. Further, the scientiﬁc evidence of
the clinical, psychological, and economic advantages of a
formal pulmonary rehabilitation program in COPD patients
continues to grow [53]. For many COPD patients, successful
participation in a pulmonary rehabilitation program entails
the need for ample portable oxygen, especially when struc-
tured walking exercise is attempted [54]. Any disruption
to the unencumbered access to unlimited portable oxygen
quickly becomes a disincentive to subsequent participation.
The aforementioned limitations can be overcome by
using newer “nondelivery” oxygen devices. This terminology
isduetothefactthatthehomecareprovidernolongerhasto
make periodic home deliveries to replenish depleted gaseous
or liquid-oxygen contents [55]. A nondelivery LTOT device
is self-suﬃcient and able to provide all of the oxygen needed
to meet both stationary and ambulatory requirements.
It can be considered a very cost-eﬀective alternative to
the expenditures of maintaining traditional stationary and
portable systems with repeat home deliveries.
As mentioned earlier, studies addressing LTOT have
been primarily descriptive and frequently have not included
behavioral or psychological approaches. Although some
qualitative research has hitherto been performed on LTOT
adherence, research focused on the patient’s perspective
should be expanded [45]. Cullen recently devised a practical
research agenda pertinent to identifying research necessary
for improving adherence to LTOT (Figure 1).
This research rubric points to four domains for explo-
ration;treatmentcomplexityandhealthcarebarriers,aspects6 Pulmonary Medicine
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Figure 1: Long-term oxygen therapy: a research agenda for com-
pliance.
related to information and education, and psychosocial,
emotional, and behavioral domains. When investigated
against clinical outcome measures and quality of life indica-
tors,thesebroadcategoriescomposearesearchagenda.Elab-
orating the research agenda may advance clinical outcomes,
quality of life, and self-management knowledge. Only then
can comprehensive guidelines be constructed to assist with
oxygen self-management.
6. Conclusion
It is well substantiated that suboptimal adherence with long-
term oxygen therapy is common and causes signiﬁcant
morbidity as well as great expenses to healthcare systems
universally. When prescribing medication, it may be impor-
tant to consider the complexity of the regimen in addition
to the eﬃcacy of the intervention. Oxygen is a controller
medication, according to the international pharmacopoeia
grade, and should be dispensed only upon the written
order of a licensed physician. Inappropriate use of oxygen
and oxygen-delivery equipment has the potential to result
in real harm or injury to the public and cause economic
implications. Clinicians involved in LTOT need to be aware
and work with the patients to facilitate their use of oxygen.
Improving adherence to oxygen therapy and minimizing
the negative impacts of the therapy require understanding
the subjective experience of the therapy. Exploring patients’
concerns and prejudices about oxygen therapy can assist
withthedevelopmentofnewinterventionsandmanagement
strategies. Moreover, worthwhile goals for future research
include the development of better strategies for patient
education and more tolerable methods for oxygen delivery
(e.g., oxygen-conserving systems, nondelivery long-term
oxygen systems), together with testing of these approaches
to verify their eﬀectiveness in improving the outcomes of
patients receiving LTOT.
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